ReviewNature chemical biology2021
Chains of evidence from correlations to causal molecules in microbiome-linked diseases.
Review in Nature chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review exploring the association between the human gut microbiota and brain connectivity in health and disease.Molecular psychiatry · 2023Pooled it
- Phenotypic high-throughput screening identifies modulators of gut microbial choline metabolism.mBio · 2026Article
- Role of Acid-Sensing Ion Channels 1a in the Regulation of Obesity and the Gut Microbiota.Obesity (Silver Spring, Md.) · 2026Article
- Opposite regulatory effects ofFrontiers in neurology · 2026Article
- The immune anatomy of the small intestine facilitates regulatory responses.Frontiers in immunology · 2026Review
- Gut microbiota phospholipids regulate intestinal gene expression and can counteract the effects of antibiotic treatment.Research square · 2025Article
- Gut microbiome and postbiotics: bridging the dietary nutrition and feed efficiency in food-producing animals.Science China. Life sciences · 2025Review
- A novel framework for assessing causal effect of microbiome on health: long-term antibiotic usage as an instrument.Gut microbes · 2025Article
- Article
- Article
- From bugs to brain: unravelling the GABA signalling networks in the brain-gut-microbiome axis.Brain : a journal of neurology · 2025Review
- Alterations in intestinal bile acid transport provide a therapeutic target in patients with post-bariatric hypoglycaemia.Nature metabolism · 2025Article
- Precision microbial regulation: Strategies for modulating GIT microbiota for host health.iMetaOmics · 2025Article
- Human Gut Microbiome Researches Over the Last Decade: Current Challenges and Future Directions.Phenomics (Cham, Switzerland) · 2025Article
- Integrated Microbiome and Metabolomic to Explore the Mechanism of Coptisine in Alleviating Ulcerative Colitis.Phytotherapy research : PTR · 2025Article
- Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy.Frontiers in immunology · 2025Review
- Biosynthetic enzyme analysis identifies a protective role for TLR4-acting gut microbial sulfonolipids in inflammatory bowel disease.Nature communications · 2024Article
- Review
- The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetes care · 2024Review
- The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetologia · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Human-associated microorganisms play a vital role in human health, and microbial imbalance has been linked to a wide range of disease states. In this Review, we explore recent efforts to progress from correlative studies that identify microorganisms associated with human disease to experiments that establish causal relationships between microbial products and host phenotypes. We propose that successful efforts to uncover phenotypes often follow a chain of evidence that proceeds from (1) association studies; to (2) observations in germ-free animals and antibiotic-treated animals and humans; to (3) fecal microbiota transplants (FMTs); to (4) identification of strains; and then (5) molecules that elicit a phenotype. Using this experimental 'funnel' as our guide, we explore how the microbiota contributes to metabolic disorders and hypertension, infections, and neurological conditions. We discuss the potential to use FMTs and microbiota-inspired therapies to treat human disease as well as the limitations of these approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.